Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to determine the safety and effectiveness of the aerSleep® II device for treatment of moderate to severe Obstructive Sleep Apnea (OSA) over 24 weeks of home use in spontaneously breathing adult subjects who are intolerant of Continuous Positive Airway Pressure (CPAP) therapy.
This is a multi-center, single-arm, prospective, observational intervention study to determine the safety and effectiveness of the aerSleep II System. Up to 900 subjects will be enrolled at up to 30 study sites in the United States and outside the United States to ensure that approximately 79 subjects who are termed initial responders can be evaluated after 24 weeks of home use with the aerSleep II device. As part of screening and prior to intervention, home sleep testing will be performed to establish baseline apnea-hypopnea index (AHI). Subjects meeting study criteria will wear the aerSleep II device at home. After a 1-week period of acclimation, subjects will have a second HST (HST #2). Initial responders with a ≥50% reduction in AHI from baseline with an AHI <20/hour will be continued on home treatment. Non-responders will be discontinued from the study. After 12 weeks, subjects will have an interim home sleep study. After 24 weeks of home use, subjects will have HST #4 to determine the primary effectiveness endpoint.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| aerSleep II | Experimental | Use of aerSleep II device to provide continuous external negative pressure to treat moderate to severe OSA in spontaneously breathing subjects who are intolerant of CPAP |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| aerSleep II | Device | Continuous negative external pressure (cNEP) system that maintains an open airway by applying negative pressure to the anterior neck via a soft silicone collar |
| Measure | Description | Time Frame |
|---|---|---|
| Sustained response to aerSleep II therapy at 24 weeks | The primary effectiveness endpoint is to demonstrate that a majority of adult subjects who are initial responders to aerSleep II therapy experience a change of at least 50% of their baseline AHI with an AHI rate less than 20 per hour at the final home sleep test at 24 weeks. | 24 weeks |
| Adverse Device Effects | The primary safety endpoint is to characterize the adverse device effects experienced throughout the study. | 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| ODI change | Demonstrate a change in Oxygen Desaturation Index (ODI) at HST #4 compared to baseline HST for initial responders | 24 weeks |
| AHI change from baseline for all subjects that acclimate to the aerSleep II device |
Not provided
Inclusion Criteria:
Age ≥ 18 years old
Body mass index ≤42 kg/m2
Prior documented diagnosis of OSA by means of a polysomnography (PSG) test or home sleep test (HST)
Documented evidence from a screening HST following consent to demonstrate:
Previous treatment attempt with CPAP resulting in failure to treat or discontinuation due to intolerance, subject choice, or struggle to use CPAP
Have not used CPAP or oral appliances within 1 week of the screening home sleep test and agree not to use CPAP or oral appliances throughout the study duration
Access to and ability to use a smart device such as a smartphone or tablet
Able to speak, read, and write English
In the opinion of the investigator, the subject will be able to understand and comply with all study procedures.
Exclusion Criteria:
Known sleep disorder other than OSA, such as narcolepsy, restless leg syndrome, idiopathic hypersomnolence or chronic insomnia
Craniofacial abnormalities that may be contributing to OSA
Previous surgery, injury, or radiation to the neck which, in the Investigator's judgment, could interfere with collar fit or comfort
Excessive hair or beard in the area of the neck where the collar will be placed, and/or unwillingness to shave that area for the duration of this study
Inflammatory skin condition, such as acne or eczema in the area where the collar will be affixed to the skin, which, in the Investigator's judgment, could interfere with collar fit or comfort
Known silicone allergy
Night shift work because of irregular sleep-wake cycles
Excessive alcohol intake, defined as that leading to interference with work, home life, or the ability to optimally perform normal everyday duties and tasks
Use of illicit drugs currently or within the past 5 years
Serious pulmonary disease (e.g., cor pulmonale, CO2 retention, or poorly controlled asthma)
Use of home oxygen or baseline oxygen saturation <94%
Cancer that has been in remission for less than one year
Psychiatric illness that, in the opinion of the Investigator, is not reasonably well-controlled with treatment
Serious cardiac disease (e.g., congestive heart failure, unstable coronary artery disease, or poorly controlled rhythm disturbance)
Prior carotid endarterectomy, prior percutaneous coronary angiography (including any placement of carotid stents), or known stenosis of either internal carotid artery > 70% from prior carotid imaging (e.g., carotid duplex ultrasound, angiography, computed tomography angiography, or magnetic resonance angiography)
Previous surgery for peripheral arterial disease
Presence of possible or definite carotid artery disease, defined as any of the following:
Tonsil size 3 or 4 (Appendix C)*
Currently pregnant* or planning to become pregnant during participation in this study
Unable to obtain adequate collar fit*
Any condition or circumstance that, in the opinion of the investigator, may preclude study completion, interfere with accurate data collection, or bias the results
The investigator believes that the subject's participation may not be in his or her best interest
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kingman P. Strohl, M.D. | Case Western Reserve University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Arizona | Tucson | Arizona | 85719 | United States | ||
| Preferred Research Partners |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Determine the proportion of subjects that acclimate to the device that exhibit a change in AHI after 24 weeks of home use with the aerSleep II device
| 24 weeks |
| Change in sleep disturbance from baseline as measured by Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance questionnaire | Determine the change in sleep disturbance at the end of the study compared to baseline using the validated PROMIS Short Form Sleep Disturbance 8b questionnaire | 24 weeks |
| Change in sleep impairment from baseline as measured by PROMIS Sleep Sleep-Related Impairment questionnaire | Determine the change in sleep impairment at the end of the study from baseline as measured by the validated PROMIS Short Form Sleep-Related Impairment 8a questionnaire | 24 weeks |
| Change in sleep from baseline as measured by Patient Global Impression Scale questionnaire | Determine any change in sleep at the end of the study from baseline as measured by the Patient Global Impression Scale questionnaire | 24 weeks |
| Little Rock |
| Arkansas |
| 72211 |
| United States |
| Infinitive Bioresearch | Los Angeles | California | 90048 | United States |
| BetterNight | San Diego | California | 92123 | United States |
| Delta Waves | Colorado Springs | Colorado | 80918 | United States |
| Baptist Hospital | Miami | Florida | 33176 | United States |
| Clayton Sleep Institute | St Louis | Missouri | 63123 | United States |
| The MetroHealth System | Cleveland | Ohio | 44109 | United States |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | United States |
| The Ohio State University | Columbus | Ohio | 43210 | United States |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | United States |
| UPMC | Pittsburgh | Pennsylvania | 15213 | United States |
| Bogan Sleep Consultants | Columbia | South Carolina | 29201 | United States |
| BioSerenity | Columbia | South Carolina | 29212 | United States |
| Sleep Therapy & Research Center | San Antonio | Texas | 78229 | United States |
| ID | Term |
|---|---|
| D020181 | Sleep Apnea, Obstructive |
| D012891 | Sleep Apnea Syndromes |
| D001049 | Apnea |
| ID | Term |
|---|---|
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D012818 | Signs and Symptoms, Respiratory |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided